| Pharmaceutical Information |
| Drug Name |
Mepolizumab |
| Drug ID |
BADD_D01389 |
| Description |
Eosinophils are involved in inflammatory immune responses, and prolonged hypereosinophilia (typically defined as absolute eosinophil levels of 1500/mm3 or more) is associated with a spectrum of diseases, including severe asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES). The pathogenesis of eosinophilia is complex, but IL-5 is recognized as a key cytokine involved in the differentiation, recruitment, activation, and prolonged survival of eosinophils in peripheral tissue. Activated eosinophils further stimulate an inflammatory response and also induce tissue lesions and promote fibrosis, all of which contribute to the multifactorial symptomatology of hypereosinophilic diseases.[A221048, A221053, A221058, A221063, A221068, L16518]
Mepolizumab is a fully-humanized recombinant IgG1 kappa monoclonal antibody directed against IL-5 produced in Chinese hamster ovary cells. Mepolizumab was first approved by the FDA on November 4, 2015, as an add-on therapy for severe asthma and marketed under the brand name Nucala by GlaxoSmithKline. This indication was subsequently expanded to cover EGPA on December 12, 2017, and HES on September 25, 2020.[L16518] |
| Indications and Usage |
Mepolizumab is indicated for add-on maintenance treatment of severe eosinophilic asthma, as identified by blood eosinophils greater than or equal to 150 cells/μl at initiation of treatment or blood eosinophils greater than or equal to 300 cells/μl in the past 12 months, in patients aged 12 years and older. Mepolizumab has been shown to reduce exacerbations of asthma in patients with an exacerbation history |
| Marketing Status |
Prescription |
| ATC Code |
R03DX09 |
| DrugBank ID |
DB06612
|
| KEGG ID |
D04923
|
| MeSH ID |
C434107
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D03MTN
|
| NDC Product Code |
49401-012; 0173-0881; 58437-009; 58437-004; 0173-0904; 0173-0892 |
| Synonyms |
mepolizumab | Bosatria | SB-240563 | SB240563 | Nucala |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
196078-29-2 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
